• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
EXOGEN Ultrasound Bone Healing System
Pin It

Bioventus, a global leader in orthobiologic solutions, has received notice from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG12) regarding the use of the EXOGEN Ultrasound Bone Healing System for treatment of long bone fractures with nonunion.

EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process and promote fracture healing. 1 It also has an 86% heal rate for fractures not healing on their own 2 and provides 38% faster healing of fresh fractures.

NICE reviewed a large body of clincial evidience, and based on the findings of its external assessment centre (EAC), will maintain its recommended use specific to EXOGEN for treatment of long bone fractures with nonunion, which NICE defines as fractures that fail to heal after nine months.

In addition, the EAC reviewed and updated the cost parameters in its original cost modelling and found that while the cost of revision surgery has increased 25%, costs related to the use of EXOGEN to treat long bone fractures with nonunion has remained the same since its last published review in 2013. This has resulted in the doubling of cost savings to £2,407 (previously £1,164) per patient, compared with current care management, through avoiding surgery.

“EXOGEN has been a proven alternative to patients seeking to heal long bone nonunion fractures and avoid surgery for many years,” said Tony Bihl, CEO, Bioventus. ”This updated guidance from NICE continues its previous recommendation for use and underscores the cost savings gained by patients suffering from nonunions which provides significant economic relief to the health care system in the United Kingdom.”

“EXOGEN has also been a proven adjunctive therapy for surgically treated fractures and has many Level-1 studies showing its positive effect on fracture healing,” said Peter Shaw, MBBS DRCOG, Chief Medical Officer, Bioventus. “Both the updated clinical and economic evidence presented in this amended guidance to MTG12 strongly support a clinicians’ decision to prescribe EXOGEN and, most importantly, provide positive outcomes for patients.”

For more information, visit www.BioventusGlobal.com

Company Name: Bioventus
About Company: Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
Person of Contact: Thomas Hill
Phone: 919-474-6715
e-Mail: Mailto: thomas.hill@bioventusglobal.com

We use cookies to ensure you get the best experience on this website Privacy Policy